skip to main content

H.R. 153: Protecting Consumer Access to Generic Drugs Act of 2021

Call or Write Congress

React to this bill with an emoji

Save your opinion on this bill on a six-point scale from strongly oppose to strongly support

Add Note All Positions »
(About Ads | Hide These Ads)

To prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable product manufacturers to delay entry of biosimilar and interchangeable products, and for other purposes.

The bill’s titles are written by its sponsor.

Sponsor and status

Photo of sponsor Bobby Rush

Bobby Rush

Sponsor. Representative for Illinois's 1st congressional district. Democrat.

Thumbnail of bill text
Read Text »
Last Updated: Jan 4, 2021
Length: 20 pages
Introduced
Jan 4, 2021
117th Congress (2021–2023)
Status

Introduced on Jan 4, 2021

This bill is in the first stage of the legislative process. It was introduced into Congress on January 4, 2021. It will typically be considered by committee next before it is possibly sent on to the House or Senate as a whole.

Cosponsors

15 Cosponsors (14 Democrats, 1 Republican)

Prognosis
3% chance of being enacted according to Skopos Labs (details)
Source
Congress.gov

History

Apr 17, 2007
 
Earlier Version — Introduced

This activity took place on a related bill, H.R. 1902 (110th).
Mar 25, 2009
 
Earlier Version — Introduced

This activity took place on a related bill, H.R. 1706 (111th).
Feb 9, 2012
 
Earlier Version — Introduced

This activity took place on a related bill, H.R. 3995 (112th).
Dec 11, 2013
 
Earlier Version — Introduced

This activity took place on a related bill, H.R. 3709 (113th).
Apr 3, 2019
 
Earlier Version — Ordered Reported

This activity took place on a related bill, H.R. 1499 (116th).
Jan 4, 2021
 
Introduced

Bills and resolutions are referred to committees which debate the bill before possibly sending it on to the whole chamber.

Read Text »

May 4, 2021
 
Considered by Health

A committee held a hearing or business meeting about the bill.

If this bill has further action, the following steps may occur next:
—
 
Passed Committee

—
 
Passed House

—
 
Passed Senate

—
 
Signed by the President

H.R. 153 is a bill in the United States Congress.

A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.

Bills numbers restart every two years. That means there are other bills with the number H.R. 153. This is the one from the 117th Congress.

How to cite this information.

We recommend the following MLA-formatted citation when using the information you see here in academic work:

“H.R. 153 — 117th Congress: Protecting Consumer Access to Generic Drugs Act of 2021.” www.GovTrack.us. 2021. June 23, 2021 <https://www.govtrack.us/congress/bills/117/hr153>

Where is this information from?

GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.